Correspondence: ACMD advice on the classification and schedule of Remimazolam

⌂Back To Homepage Subscribe To RSS Feed

Advisory Council On The Misuse Of Drugs

December 2

11:00 2022

Print This Article Share it With Friends

Created by Advisory Council On The Misuse Of Drugs 0 comments

ACMD advice on the classification and schedule of Remimazolam

HTML

ACMD advice on the classification and schedule of Remimazolam

PDF, 115 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need aversion of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk.Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The ACMD is grateful to the Medicines and Healthcare products Regulatory Agency (MHRA) for providing a written dossier and oral presentation on the ultra-short-acting Benzodiazepine Remimazolam (Byfavo).

Further to these representations, the ACMD is able to provide advice regarding the appropriate classification and schedule for this medicine.

Published 2 December 2022

Your name:	Your email:
Comments:
Post my comment

GovWire